Humanin for Cellular Protection

Candidate profile

Adults interested in mitochondrial-derived peptide therapy for generalized cytoprotection — reducing cellular stress, improving metabolic resilience, and supporting organ function in the context of aging. Humanin is of particular interest to individuals already using or exploring MOTS-c (another mitochondrial-derived peptide), as they target complementary aspects of mitochondrial biology.

Humanin is deeply investigational. It was discovered in 2001 as the first mitochondrial-derived peptide (MDP) and has robust preclinical data across multiple disease models. No human therapeutic trials have been conducted. This is a research peptide for the biologically literate.

Approach

Subcutaneous injection of humanin (or its analog HNG — humanin with a glycine-to-serine substitution at position 14, which increases potency ~1000-fold). Humanin is a 24-amino-acid peptide encoded by the mitochondrial genome that acts as an endogenous cytoprotective signal. It binds to three distinct receptor systems — FPRL1 (formyl peptide receptor), the IL-6/CNTF tripartite receptor (gp130/IL-6R/WSX-1), and BAX (direct binding) — to inhibit apoptosis, reduce ER stress, improve insulin sensitivity, and protect against amyloid-beta toxicity.

Protocol design

Primary peptide: Humanin or HNG analog, 1–4 mg daily

Route: Subcutaneous injection

Timing: Morning

Duration: 4–8 weeks per cycle, with extended washout periods

Frequency: Daily during the active cycle

Dosing context: Humanin dosing is extrapolated from rodent studies. The HNG analog is preferred in practice due to its markedly higher potency and stability. Endogenous humanin levels decline with age — centenarian offspring have higher circulating humanin levels than age-matched controls, suggesting a longevity association.

Mechanistic breadth: Humanin is unusually broad-spectrum among peptides. Preclinical protection has been demonstrated in:

• Neuronal models (Alzheimer's amyloid toxicity)
• Cardiac models (ischemia-reperfusion injury)
• Endothelial models (oxidative stress)
• Pancreatic beta cells (glucolipotoxicity)
• Testicular cells (chemotherapy-induced damage)

Timeline & milestones

Weeks 1–2: No perceptible changes. Humanin's cytoprotective effects operate at the cellular signaling level — upregulating anti-apoptotic pathways and chaperone responses.

Weeks 2–4: Potential early signals: improved recovery from exercise (reduced cellular stress), improved fasting glucose (insulin-sensitizing effects), and possibly improved sleep quality. These are subtle and difficult to attribute.

Weeks 4–8: If the mechanism translates, measurable improvements in metabolic markers (HOMA-IR, fasting insulin), inflammatory markers (CRP), and possibly oxidative stress biomarkers (F2-isoprostanes, 8-OHdG).

Post-cycle: Unknown duration of benefit. Endogenous humanin production continues; exogenous supplementation temporarily augments a natural signal.

Monitoring

• Metabolic panel: Fasting glucose, insulin, HOMA-IR at baseline and monthly — the most measurable endpoint
• Inflammatory markers: CRP, IL-6 at baseline and monthly
• Oxidative stress markers (if available): F2-isoprostanes, 8-OHdG — research-grade but directly relevant to humanin's mechanism
• Complete blood count: Baseline and post-cycle — humanin modulates hematopoietic progenitor cell survival
• IGF-1: Humanin signaling intersects with the GH/IGF-1 axis — monitor for unexpected changes
• Subjective recovery and energy logs: Daily tracking

When to adjust

• No change in any measurable biomarker by week 6: Discontinue. Without human PK data, it is unknown whether subcutaneous humanin achieves tissue concentrations sufficient for the preclinical effects observed.
• Injection site reactions: Rotate sites. If persistent, consider the HNG analog if using native humanin.
• Unexpected glucose changes: Humanin should improve insulin sensitivity; deterioration suggests confounding factors.
• Any allergic-type reaction: Discontinue. Humanin is an endogenous peptide, but supraphysiological dosing of any signaling molecule can produce unexpected immune responses.

Evidence reality check

Humanin has a more robust preclinical portfolio than most research peptides — over 200 published papers demonstrating cytoprotection across tissue types. The centenarian offspring association provides intriguing epidemiological support. The mechanistic story is coherent: a mitochondrial-encoded peptide that signals cellular protection when mitochondria are stressed. However, the translation from petri dish and mouse to human therapy is entirely uncharacterized. Circulating humanin levels are in the picomolar range endogenously — the relationship between these levels and pharmacological subcutaneous dosing is unknown. This is a biologically fascinating peptide with zero clinical validation.